Literature DB >> 31130367

Different patterns and specific outcomes of large-vessel involvements in giant cell arteritis.

Hubert de Boysson1, Eric Liozon2, Olivier Espitia3, Aurélie Daumas4, Mathieu Vautier5, Marc Lambert6, Jean-Jacques Parienti7, Brigitte Granel4, Anael Dumont8, Audrey Sultan8, Alain Manrique9, David Saadoun10, Kim Heang Ly2, Christian Agard3, Achille Aouba11.   

Abstract

Large-vessel involvement (LVI) in giant cell arteritis (GCA) includes different clinical and imaging patterns that are rarely described separately at diagnosis and whose specific cardiovascular outcomes are unknown. We conducted a nationwide retrospective study and included GCA patients with LVI demonstrated on imaging at diagnosis between 2007 and 2017. We analyzed the prognosis of three different imaging patterns of LVI present at diagnosis, with some of them overlapping but with the first one present in all patients: 1) inflammation of the aorta and/or its branches; 2) dilation of the aorta; and 3) stenosis of the aortic branches. A control group of GCA patients without LVI was constituted. We included 183 patients with LVI and 105 controls without LVI. Altogether, among the 183 patients who all showed inflammation of the aorta and/or its main branches, concomitant aortic dilation and large-vessel stenosis were observed in 27 (15%) and 55 (30%) patients, respectively. During the follow-up period, new cardiovascular events occurred in 49% and 11% of LVI patients and controls, respectively (p < 0.0001). Inflammation of the aorta and/or its branches (HR: 3.42 [2.09-5.83], p < 0.0001) and large-artery stenosis (HR: 2.75 [1.80-4.15], p < 0.0001) were independent predictive factors of new cardiovascular events. Conversely, the use of an immunosuppressant besides corticosteroids was a protective factor against new cardiovascular events (HR: 0.44 [0.29-0.66], p < 0.0001) and the development of aortic dilation (HR: 0.43 [0.23-0.77], p = 0.005). This study suggests different forms of cardiovascular events according to the initial imaging pattern of LVI.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Aortic dilation; Aortic dissection; Cardiovascular outcomes; Giant-cell arteritis; Imaging patterns; Large-vessel stenosis

Year:  2019        PMID: 31130367     DOI: 10.1016/j.jaut.2019.05.011

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  10 in total

Review 1.  [Glucocorticoids in the treatment of giant cell arteritis : How much, how long and how to spare?]

Authors:  Bernhard Hellmich
Journal:  Z Rheumatol       Date:  2021-03-12       Impact factor: 1.372

2.  Magnetic resonance imaging-based diagnosis of aortitis preceding development of a thoracic aneurysm in a patient with giant cell arteritis: a case report.

Authors:  Georg Lutter; Thomas Puehler; Christoph Röcken; Marcus Both
Journal:  Eur Heart J Case Rep       Date:  2022-04-12

3.  Pericardial effusion in giant cell arteritis is associated with increased inflammatory markers: a retrospective cohort study.

Authors:  Quentin Gomes de Pinho; Aurélie Daumas; Audrey Benyamine; Julien Bertolino; Pascal Rossi; Nicolas Schleinitz; Jean-Robert Harlé; Pierre André Jarrot; Gilles Kaplanski; Julie Berbis; Brigitte Granel
Journal:  Rheumatol Int       Date:  2022-05-07       Impact factor: 3.580

Review 4.  An Updated Review of Cardiovascular Events in Giant Cell Arteritis.

Authors:  Hubert de Boysson; Achille Aouba
Journal:  J Clin Med       Date:  2022-02-15       Impact factor: 4.241

5.  Patients' Baseline Characteristics, but Not Tocilizumab Exposure, Affect Severe Outcomes Onset in Giant Cell Arteritis: A Real-World Study.

Authors:  Cyril Dumain; Jonathan Broner; Erik Arnaud; Emmanuel Dewavrin; Jan Holubar; Myriam Fantone; Benoit de Wazières; Simon Parreau; Pierre Fesler; Philippe Guilpain; Camille Roubille; Radjiv Goulabchand
Journal:  J Clin Med       Date:  2022-05-31       Impact factor: 4.964

Review 6.  [Rheumatological emergency on the edge of intensive care medicine].

Authors:  Peter Härle
Journal:  Z Rheumatol       Date:  2019-12       Impact factor: 1.372

7.  Symptomatic aortitis at giant cell arteritis diagnosis: a prognostic factor of aortic event.

Authors:  Olivier Espitia; Gauthier Blonz; Geoffrey Urbanski; Cédric Landron; Jérôme Connault; Christian Lavigne; Pascal Roblot; François Maillot; Alexandra Audemard-Verger; Mathieu Artifoni; Cécile Durant; Béatrice Guyomarch; Mohamed Hamidou; Julie Magnant; Christian Agard
Journal:  Arthritis Res Ther       Date:  2021-01-07       Impact factor: 5.156

8.  Evaluation of adjunctive mycophenolate for large vessel giant cell arteritis.

Authors:  Maira Karabayas; Paula Dospinescu; Nick Fluck; Dana Kidder; Gillian Fordyce; Rosemary J Hollick; Cosimo De Bari; Neil Basu
Journal:  Rheumatol Adv Pract       Date:  2020-12-19

9.  Risk factors for symptomatic vascular events in giant cell arteritis: a study of 254 patients with large-vessel imaging at diagnosis.

Authors:  Donatienne de Mornac; Christian Agard; Jean-Benoit Hardouin; Mohamed Hamidou; Jérôme Connault; Agathe Masseau; Alexandra Espitia-Thibault; Mathieu Artifoni; Chan Ngohou; François Perrin; Julie Graveleau; Cécile Durant; Pierre Pottier; Antoine Néel; Olivier Espitia
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-06-27       Impact factor: 5.346

Review 10.  Advances in the Treatment of Giant Cell Arteritis.

Authors:  Santos Castañeda; Diana Prieto-Peña; Esther F Vicente-Rabaneda; Ana Triguero-Martínez; Emilia Roy-Vallejo; Belén Atienza-Mateo; Ricardo Blanco; Miguel A González-Gay
Journal:  J Clin Med       Date:  2022-03-13       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.